Skip to main content

Advertisement

Table 3 Subgroup analysis of stem cell therapy in LVEF

From: Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis

Subgroup Follow-up No. of studies Mean difference 95% CI P
Injection route
 Intracoronary 3 months 6 4.96 3.42, 6.51 < 0.0001
6 months 4 3.62 0.14, 7.11 0.04
≥ 12 months 9 3.80 0.19, 7.40 0.04
 Intramyocardial 3 months 2 2.24 − 3.25, 7.72 0.42
6 months 4 5.29 1.94, 8.65 0.002
≥ 12 months 3 1.15 − 1.30, 6.30 0.36
Cell type
 BMSC 3 months 6 4.58 3.74, 5.43 < 0.0001
6 months 5 5.19 3.24, 7.04 < 0.0001
≥ 12 months 5 5.04 1.00, 9.02 0.01
 BMNC 3 months 4 3.77 2.25, 5.28 < 0.0001
6-month 3 0.28 − 2.72, 3.28 0.85
≥ 12 months 8 2.97 1.04, 4.89 0.002
Dosage
 106 3 months 3 5.12 − 0.62, 10.86 0.08
6 months 3 3.23 0.79, 5.68 0.009
≥ 12 months 4 1.16 − 2.22, 4.54 0.50
 108 3 months 5 4.68 3.59, 5.77 < 0.0001
6 months 3 6.23 4.62, 7.83 < 0.0001
≥ 12 months 5 5.40 0.56, 6.64 0.0003
  1. BMNC bone marrow mononuclear cells, BMSC bone mesenchymal stem cells, LVEF left ventricular ejection fraction